CEO Executive AssistantLicensing and partnerships are strategic lifelines for pharmaceutical companies. In-licensing fills pipeline gaps. Out-licensing monetizes assets and shares development risk. Co-development partnerships spread the cost of expensive clinical programs. Each deal type requires a carefully calibrated approach to CEO involvement and operational delegation.
This article provides specific delegation strategies for pharma CEOs managing active licensing and partnership programs.
Understanding the CEO’s Licensing Role
The pharma CEO’s unique contribution to licensing and partnerships is at the level of strategy, relationship, and final deal authority. Specifically:
In-licensing target criteria. What therapeutic areas, what compound stages, what deal structures, and what financial profiles represent attractive in-licensing targets? These criteria come from the CEO and board in alignment with organizational strategy.
Out-licensing strategy. Which assets are candidates for out-licensing? What deal structures optimize value while maintaining mission alignment? What partner profiles are preferred? These are CEO-level strategy decisions.
Executive counterpart negotiations. When licensing discussions reach the senior level (CEO-to-CEO or CEO-to-CSO negotiations), CEO presence is often critical to closing deals.
Deal approval. Material licensing transactions require CEO approval and often board approval.
Strategic partnership relationships. For major collaboration partners (large pharma co-development partners, major academic collaborators), the CEO maintains the strategic relationship while operational details are delegated.
Delegation Strategies for In-Licensing Operations
Strategy One: Empowered BD Team with Clear Deal Criteria
The most effective in-licensing delegation model begins with documented deal criteria that empower the BD team to source, screen, and advance opportunities independently.
The BD team should be able to:
- Source opportunities through their networks without CEO guidance on targets
- Conduct initial assessment using established criteria
- Advance promising opportunities to due diligence without CEO review at the screening stage
- Present only qualified, well-analyzed opportunities to the CEO
This requires investing time upfront in developing clear criteria and building BD team capability and judgment.
Strategy Two: Phased CEO Involvement
Structure CEO involvement in tiers:
- Phase one (sourcing and screening): Fully delegated to BD team
- Phase two (due diligence): BD team manages; CEO informed via monthly pipeline update
- Phase three (term sheet negotiation): BD leadership leads; CEO reviews key terms before counterparty engagement
- Phase four (final negotiation and close): CEO engages for major deals; BD leadership manages smaller deals through close
Strategy Three: Leveraged Advisor Network
External advisors (investment banks, licensing advisors, scientific consultants) can significantly extend the BD team’s capacity. Managing these advisors is a BD and legal function. The CEO approves the engagement of significant advisors but does not manage them.
Delegation Strategies for Out-Licensing Operations
Strategy One: Asset Positioning Process
Before out-licensing a compound or platform, a cross-functional team (BD, clinical, regulatory, commercial) should develop an asset positioning package documenting clinical profile, regulatory status, IP coverage, and valuation. The CEO reviews and approves the positioning before BD engages potential partners.
Strategy Two: Partnering Conference Presence
Major pharmaceutical partnering conferences (BIO International, JPMorgan Healthcare Conference, BioEurope) provide concentrated opportunities for licensing discussions. The BD team manages conference logistics, schedules meetings, and conducts initial discussions. The CEO participates in select high-priority meetings.
Strategy Three: Parallel Process Management
When out-licensing a high-value asset, running a parallel process with multiple potential partners maximizes competition and value. Managing a parallel process (coordinating NDAs, managing data room access, orchestrating negotiations) is a BD operations function.
Partnership Governance Delegation
For ongoing strategic partnerships, operational management should be fully delegated:
Joint Steering Committee participation. For major co-development partnerships, a Joint Steering Committee or equivalent governance body meets regularly. BD leadership or program leadership participates in routine JSC meetings. The CEO participates only in escalation discussions or strategic re-direction meetings.
Partnership reporting. Preparing and delivering progress reports to partners is a program management function.
Day-to-day collaboration coordination. Research collaboration activities, data sharing, and technical coordination between partner teams are managed by program teams.
For pharma CEOs building comprehensive BD and licensing delegation frameworks, delegation framework for pharma CEO: business development provides the operational foundation for licensing delegation.
The broader pharmaceutical executive delegation model, including how chiefs of staff support BD coordination, is covered in what pharmaceutical biotech CEOs delegate to their chief of staff.
Building Licensing Delegation Infrastructure
Opportunity Tracking System
A CRM or opportunity tracking system maintained by the BD team provides pipeline visibility without CEO involvement in day-to-day tracking.
Deal Authority Thresholds
Clear dollar and strategic thresholds for deal approval prevent both under-delegation (every small deal goes to the CEO) and over-delegation (major transactions proceed without CEO review).
NDA and Data Room Management Protocols
Standard processes for managing non-disclosure agreements, data room access, and confidential information sharing enable the BD team to advance discussions efficiently without CEO involvement in each documentation step.
Conclusion
Licensing and partnerships are high-impact activities that benefit from strong operational BD infrastructure and targeted CEO engagement. The pharma CEO who builds an empowered BD team, establishes clear deal criteria, and personally engages at strategic relationship and negotiation moments will build a licensing program that creates significant organizational value.
Empower the BD team. Set the strategy. Close the deals that matter most.
For pharmaceutical licensing and business development strategy, see Forbes.com/business pharmaceutical strategy resources.
Related Reading
For further context, explore Delegation Strategies for Asset Management CEO and Delegation Strategies for Automotive CEO: Digital Retail.